Skip to main
DCTH
DCTH logo

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc. is projecting a remarkable increase in total revenues, forecasting growth from $82.3 million in 2025 to $338.7 million by 2032, indicating a robust long-term growth trajectory. The company has demonstrated consistent quarterly growth in HEPZATO-related revenue since its launch, with a reported 37% quarter-over-quarter increase in the expected revenue for the HEPZATO KIT in the fourth quarter of 2024. Additionally, new site activations suggest a strong adoption of their product, supporting ongoing revenue growth and a promising pipeline leading into 2025.

Bears say

Delcath Systems Inc has faced significant challenges in terms of revenue growth and sustained profitability, reflecting broader concerns about the commercial viability of its Melphalan Hydrochloride for Injection product and its delivery system. The company's financial statements suggest increasing operational costs without a corresponding increase in sales, leading to persistent net losses that raise doubts about its ability to secure additional funding. Moreover, the market for oncology treatments is highly competitive and heavily regulated, which could further hinder Delcath's performance and its strategic positioning within the oncology sector.

Delcath Systems (DCTH) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.